New Targetable Vulnerability in Fusion-Positive Rhabdomyosarcoma
Author Information
Author(s): Hsieh Joseph, Danis Etienne P., Owens Charles R., Parrish Janet K., Nowling Nathan L., Wolin Arthur R., Purdy Stephen Connor, Rosenbaum Sheera R., Ivancevic Atma M., Chuong Edward B., Ford Heide L., Jedlicka Paul
Primary Institution: University of Colorado Anschutz Medical Campus
Hypothesis
How do KDM3A and ETS1 interact with PAX3-FOXO1 to drive aggressive properties in fusion-positive rhabdomyosarcoma?
Conclusion
The study reveals that the KDM3A/ETS1 regulatory module enhances PAX3-FOXO1 chromatin occupancy, promoting aggressive characteristics in fusion-positive rhabdomyosarcoma.
Supporting Evidence
- KDM3A and ETS1 co-localize with PAX3-FOXO1 at enhancers of important disease-promoting genes.
- Disruption of the PAX3-FOXO1/ETS1 complex by YK-4-279 inhibits growth and invasive properties in FP-RMS.
- Downregulation of FGF8, IL4R, MEST, and PODXL expression was observed following treatment with YK-4-279.
Takeaway
Researchers found that two proteins, KDM3A and ETS1, help a cancer-causing protein called PAX3-FOXO1 do its job better, making the cancer more aggressive. They also discovered a drug that can stop this process.
Methodology
The study utilized CUT&RUN cistrome profiling to analyze chromatin localization and gene expression in patient-derived FP-RMS cells.
Participant Demographics
Patient-derived FP-RMS cells were used for the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website